Life sciences services and contract research organization firm Pharmaceutical Product Development is beefing up its drug discovery capabilities.
The privately held firm, which is based in Wilmington and operates a facility in the Triangle, says it has added leaders in three new areas of therapeutic focus:
- Daniel J. Burch, MD,, central nervous system
- Puneet Mohan, MD, cardiovascular/metabolism
- Alan M. Solinger, MD, rheumatology/immunology.
“In today’s environment, we are partnering with clients on complex drug development strategy and providing medical and scientific expertise that extends beyond traditional clinical trial implementation,” said Rob Dow, the global head of medical affairs for PPD and former head of global drug development at F. Hoffmann-La Roche. He leads PPD’s global product development team of six therapeutic areas. “These experts have held senior leadership roles in top biopharma companies, and their expertise will bring added strategic value to our clients,” Dow said.
